Tepoxalin targeting of ABCB1 overexpressing cancers

Patent metadata

Field	Value
Publication number	US-12313632-B2
Application number	US-201917291458-A
Country	US
Kind code	B2
Filing date	Nov 8, 2019
Priority date	Nov 9, 2018
Publication date	May 27, 2025
Grant date	May 27, 2025

Abstract

The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of cancers that exhibit elevated expression and/or amplification of the ABCB1 (MDR1) transporter, optionally for reasons related to development of chemotherapeutic resistance having occurred during treatment with an initial chemotherapeutic drug. In particular, the instant disclosure provides for identification of a cancer as possessing elevated ABCB1 expression and/or exhibiting resistance to a non-tepoxalin chemotherapeutic drug, and selecting and/or administering tepoxalin, a tepoxalin derivative and/or metabolite thereof as a therapeutic agent for such a cancer and/or subject having or at risk of developing such a cancer. Methods and compositions for therapies that combine such tepoxalin or tepoxalin-related compounds with other cancer therapies and/or chemotherapeutic agents are also provided.

First claim

We claim:

1. A method for treating a subject having cancer, the method comprising:
(a) identifying the presence in a sample of the subject of one or more of the following: (i) high ABCB1 mRNA expression levels, (ii) high ABCB1 protein expression levels and/or (iii) amplification of the ABCB1 locus, in the sample as compared to an appropriate control level; and
(b) administering tepoxalin to the subject; thereby treating the subject having cancer.

2. The method of claim 1 , wherein the cancer is selected from the group consisting of lung, colorectal, kidney, hepatic, lymphoma, bone, ovarian, biliary tract and thyroid cancer.

3. The method of claim 1 , wherein step (a) comprises identifying the presence in the sample of elevated ABCB1 mRNA expression, as compared to an appropriate control.

4. The method of claim 1 , wherein identifying step (a) comprises use of a kit for identifying high expression of ABCB1 mRNA or protein in a sample, as compared to an appropriate control level, consisting essentially of an oligonucleotide for detection of ABCB1 mRNA or an anti-ABCB1 antibody, and instructions for its use.

5. The method of claim 1 , wherein the subject is human.

6. The method of claim 1 , wherein the cancer is resistant to a non-tepoxalin chemotherapeutic drug.

7. The method of claim 1 , wherein the appropriate control level is a level that is obtained from a normal, untreated, or control sample or cell population.

8. The method of claim 6 , wherein the non-tepoxalin chemotherapeutic drug is selected from the group consisting of docetaxel, busulfan, carfilzomib, daunorubicin, doxorubicin, epirubicin, idarubicin, ixabepilone, paclitaxel, romidepsin, vincristine and vinorelbine.

9. A method for treating cancer in a subject, comprising:
(a) identifying the presence in a sample of the subject of one or more of the following: (i) high ABCB1 mRNA expression levels, (ii) high ABCB1 protein expression levels and/or (iii) amplification of the ABCB1 locus, as compared to an appropriate control level; and
(b) administering tepoxalin and a pharmaceutically acceptable carrier to the subject,
thereby treating cancer in the subject.

10. The method of claim 9 , wherein the cancer is selected from the group consisting of lung, colorectal, kidney, hepatic, lymphoma, bone, ovarian, biliary tract and thyroid cancer.

11. The method of claim 9 , further comprising administering a non-tepoxalin chemotherapeutic drug to the subject.

12. The method of claim 11 , wherein the non-tepoxalin chemotherapeutic drug is selected from the group consisting of docetaxel, busulfan, carfilzomib, daunorubicin, doxorubicin, epirubicin, idarubicin, ixabepilone, paclitaxel, romidepsin, vincristine and vinorelbine.

13. A method for treating cancer in a subject, the method comprising co-administering to a subject having a cancer possessing one or more of the following: (i) high ABCB1 mRNA expression levels, (ii) high ABCB1 protein expression levels and/or (iii) amplification of the ABCB1 locus, as compared to an appropriate control level, (a) tepoxalin and (b) a non-tepoxalin chemotherapeutic drug, thereby treating cancer in the subject.

14. The method of claim 13 , wherein the cancer is selected from the group consisting of lung, colorectal, kidney, hepatic, lymphoma, bone, ovarian, biliary tract and thyroid cancer.

15. The method of claim 13 , wherein the non-tepoxalin chemotherapeutic drug is selected from the group consisting of docetaxel, busulfan, carfilzomib, daunorubicin, doxorubicin, epirubicin, idarubicin, ixabepilone, paclitaxel, romidepsin, vincristine and vinorelbine.

Assignees

• Broad Inst Inc
• Dana Farber Cancer Inst Inc
• Inst Carlos Slim De La Salud A C

Inventors

• Corsello Steven
• Spangler Ryan
• Nagari Rohith
• Golub Todd

Classifications

• G01N33/5759 Primary

  involving compounds localised on the membrane of tumour or cancer cells · CPC title

• G01N2333/70596

  Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705 · CPC title

• C12Q2600/158

  Expression markers · CPC title

• C12Q2600/106

  Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism · CPC title

• C12Q1/6886

  for cancer (immunoassay for cancer G01N33/575) · CPC title